Shopping Cart
- Remove All
Your shopping cart is currently empty
CP-532623
😃Good
Catalog No. T15004Cas No. 261947-38-0
CP-532623, a close structural analog of Torcetrapib, is a CETP inhibitor with highly lipophilic properties. It elevates high-density lipoprotein cholesterol.
CP-532623
😃Good
Catalog No. T15004Cas No. 261947-38-0
CP-532623, a close structural analog of Torcetrapib, is a CETP inhibitor with highly lipophilic properties. It elevates high-density lipoprotein cholesterol.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $987 | 6-8 weeks | |
| 50 mg | $1,310 | 6-8 weeks | |
| 100 mg | $1,990 | 6-8 weeks |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "CP-532623"
Anacetrapib
MK-0859
T1928875446-37-0
Anacetrapib (MK-0859) (MK0859) is an effective, specific, reversible rhCETP and mutant CETP(C13S) inhibitor (IC50: 7.9 nM and 11.8 nM). Anacetrapib reduces the transfer of cholesteryl ester from HDL to LDL and/or VLDL thereby, producing an increase in serum HDL-cholesterol levels and a decrease in serum LDL-cholesterol levels.
- $30
Size
QTY
Granotapide
T31992594842-13-4In house
Granotapide is a microsomal triglyceride transfer protein (MTP) inhibitor that treats and rather prevents atherosclerosis, coronary artery disease, metabolic syndrome, obesity, diabetes mellitus, prediabetes mellitus, and hypertension.
- $210
Size
QTY
Dirlotapide
Slentrol, CP742033
T15006481658-94-0In house
Dirlotapide (CP742033) is an intestinal selective microsomal triglyceride transfer protein (MTP) inhibitor. It reduces body weight in diabetic dogs.Dirlotapide reduces food intake in a dose-dependent manner, possibly by increasing the release of peptide YY into the circulation.
- $750
Size
QTY
Obicetrapib
TA-8995, TA8995, Obicetrapib (free base), Obicetrapib, AMG-899, AMG899, AMG 899
T28225866399-87-3In house
Obicetrapib (AMG-899) is an inhibitor of cholesteryl ester transfer protein.
- $163
Size
QTY
BMS-212122
UNII-0Z473OO6GB, BMS212122, BMS 212122
T30506194213-64-4In house
BMS-212122 (UNII-0Z473OO6GB) is a potent inhibitor of microsomal triglyceride transfer protein (MTP) and has shown hypolipidemic effects in animal studies.BMS-212122 significantly reduced lipid content and monocyte-derived (CD68+) cells in atherosclerotic plaques.
- $350
Size
QTY
Lomitapide
BMS-201038, AEGR-733
T6267182431-12-5
Lomitapide (AEGR-733) is a small molecule inhibitor of microsomal triglyceride transfer protein (MTP), an enzyme located in the lumen of the endoplasmic reticulum responsible for absorbing dietary lipids and transferring triglycerides onto apolipoprotein B (apo-B) in the assembly of very-low-density lipoprotein.
- $59
Size
QTY
Dalcetrapib
RO4607381, JTT-705
T6048211513-37-0
Dalcetrapib (RO4607381), a rhCETP inhibitor (IC50=0.2 μM), increases the plasma HDL cholesterol.
- $37
Size
QTY
KD-026
SLx-4090, SLx4090, SLx 4090, KD026
T27719913541-47-6
KD-026 (SLx 4090), a microsomal triglyceride transfer protein (MTP) inhibitor(IC50 = 8.0 nM), is used in type 2 diabetes studies.
- $74
Size
QTY
Lomitapide Mesylate
BMS-201038 mesylate, AEGR-733 mesylate
T2545202914-84-9
Lomitapide Mesylate (BMS-201038 mesylate) is a methanesulfonic acid form of lomitapide, a small molecule inhibitor of microsomal triglyceride transfer protein.
- $37
Size
QTY
Torcetrapib
CP-529414
T2499262352-17-0
Torcetrapib (CP-529414) is a cholesteryl ester transfer protein (CETP) inhibitor designed to reduce the heterotypic transfer of cholesteryl ester from HDL to LDL and/or VLDL. It failed in phase III trials due to an excess of deaths.
- $30
Size
QTY
Evacetrapib
LY2484595
T62621186486-62-3
Evacetrapib (LY2484595) (LY2484595) is a potent and selective inhibitor of CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. Phase 3.
- $33
Size
QTY
Implitapide
AEGR 427
T15570177469-96-4
Implitapide is an inhibitor of microsomal triglyceride transfer protein (MTP).
- $9,028
Size
QTY
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | CP-532623, a close structural analog of Torcetrapib, is a CETP inhibitor with highly lipophilic properties. It elevates high-density lipoprotein cholesterol. |
| In vitro | CP-532623 alters the kinetics of lymph lipid transport and decreases lymph lipid transport in chylomicrons. CP-532623 is highly lymphatically transported (28% of the dose). However, it lymphatic transport is closely correlated with drug affinity for ex-vivo lymph lipoproteins or triglyceride emulsions. But, it has poorly related to solubility in mixtures of lipoprotein core and/or surface lipids [2]. |
| In vivo | CP-532623 (50 mg; p.o.; adult male greyhound dogs) treatment substantially transports into the lymphatic system (>25% dose) in fed and fasted dogs. Lymphatic triglyceride transport is significantly lower in fed dogs administered CP-532623. Food enhances oral bioavailability (from 44 to 58%, respectively) and the proportion of the absorbed dose transports via the lymph (from 61 to 86% and from 68 to 83%, respectively) [3]. |
| Molecular Weight | 598.5 |
| Formula | C27H27F9N2O3 |
| Cas No. | 261947-38-0 |
| Relative Density. | 1.38 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy CP-532623 | purchase CP-532623 | CP-532623 cost | order CP-532623 | CP-532623 chemical structure | CP-532623 in vivo | CP-532623 in vitro | CP-532623 formula | CP-532623 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.